For men who choose to have radiotherapy (external photon beam, external proton beam, or brachytherapy of some type) as first-line therapy for localized prostate cancer, a major issue is, “What if the cancer recurs after treatment?” In light of the recent decision by an FDA advisory committee not to recommend approval of high-intensity focused ultrasound […]![]()
